Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop cancer cells from dividing so they stop growing or
die. Colony-stimulating factors such as filgrastim may increase the numbers of immune cells
found in bone marrow or peripheral blood and may help a person's immune system recover from
the side effects of chemotherapy. Combining chemotherapy with rituximab and filgrastim may
kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining rituximab with chemotherapy
and filgrastim in treating patients who have Burkitt's lymphoma or Burkitt's leukemia.